to CDK1 and pCHK1 S317/S345 relative to CHK1 levels (n=3). For pCHK1 S345 and pCHK1 S317, statistical significance was calculated using the two-tailed one sample students t-test, testing whether the fold change after THZ1 for the respective siRNA oligonucleotides was different from one. Notably, using this test, no statistical significance could be detected after THZ1 treatment for neither pCHK1 S317 nor S345 for the siPNUTS samples. For pRNAPII S5, statistical significance was calculated using the two-tailed two sample students t-test, comparing fold change after THZ1 between siPNUTS and scr transfected samples. *p<0.05, **p<0. Then, half of each sample was digested with 40U of RNaseH enzyme (MB08501, NZYTech) to serve as negative control, for about 48 hours at 37ºC. Digested nucleic acids were purified with phenol-chloroform extraction, re-suspended in DNase/RNasefree water and quantified. DNA samples were diluted to a concentration of 10 μg/mL and 100 μL of solution (1 μg DNA) was loaded per well, into a positively charged nylon membrane (RPN203B, GE Healthcare), using the Bio-Dot® Microfiltration System (1703938, Bio-Rad). The DNA was cross-linked through UV irradiation (UV Stratalinker 2400, Stratagene) and membranes were blocked for 1 hr at room temperature with 5% milk in PBS 1x containing 0,05% Tween 20. Incubation with the primary antibodies (anti-dsDNA (sc-58749, Santa Cruz) and S9.6 (ENH001, Kerafast)) was performed at 4ºC overnight, followed by incubation with secondary antibody (antiMouse-HRP (170-6516, Biorad)) for 1 hour at room temperature. Detection was achieved using enhanced chemiluminescence substrates (RPN2209, GE Healthcare). 
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